Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) Stock Price & Analysis

9989 Stock Chart & Stats

HK$3.99HK$0.06(1.40%)
At close: 4:08 PM GMT+8
HK$3.75HK$4HK$4.25HK$4.510 Aug24 Aug7 Sep21 Sep6 Oct20 Oct2 Nov
Day’s Range
HKD 3.87 - HKD 4.00
52-Week Range
HKD 3.74 - HKD 5.77
Previous Close
HKD 3.94
Volume
N/A
Average Volume (3M)
492.33K
Market Cap
HKD 14.42B
Enterprise Value
HKD 4.32B
Total Cash (Recent Filing)
HKD 4.27B
Total Debt (Recent Filing)
HKD 2.86B
Price to Earnings (P/E)
187.1
Beta
0.73
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
0.12
Last Dividend Ex-Date
May 27, 2026
Dividend Yield
4.16%

Bulls Say, Bears Say

Bulls Say

Cash Generation

Strong positive operating and free cash flow in 2024–TTM, with TTM FCF up 17.5% and conversion near 0.95x net income, indicates recent earnings are supported by cash. That provides capacity to fund operations and investments without relying entirely on external capital.

Balance Sheet

Debt-to-equity of about 0.18–0.25 in 2024–TTM, down from roughly 0.50+ in 2021–2022, and equity around HK$12B indicate a comparatively solid capital base. Lower leverage should preserve financial flexibility as the company manages uneven profitability.

Profitability Recovery

After negative margins in 2023, the company returned to positive earnings in 2024, 2025 and TTM. This recovery confirms the business has regained profitability, creating a foundation for improvement if revenue stabilizes and operating performance strengthens.

Bears Say

Revenue Contraction

TTM revenue declined about 3.0%, showing that recent business activity is not expanding despite the return to profitability. Continued contraction could limit operating leverage, reduce resources available for development, and make future earnings more dependent on cost control.

Margin Compression

TTM net margin fell to about 3.7% from 6.4% in 2025 and 12.2% in 2024, while ROE was only about 1.6%. This weaker profitability reduces the earnings buffer, limits internally funded growth, and indicates capital is currently producing modest returns.

Cash Flow Volatility

Cash flow was negative in 2021–2022 and weak in 2023 before improving in 2024–TTM. This multi-year volatility makes cash generation less dependable across cycles, potentially complicating investment planning and reducing confidence that recent strength will persist.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H News

9989 FAQ

What was Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price range in the past 12 months?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H lowest stock price was HK$3.74 and its highest was HK$5.77 in the past 12 months.
What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s market cap?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s market cap is HK$14.42B.
When is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s upcoming earnings report date?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s next earnings report is estimated for Apr 01, 2027 (not yet confirmed), which is in 149 days.
How were Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s earnings last quarter?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H released its earnings results on Oct 29, 2026. The company reported HK$0.095 earnings per share for the quarter, missing the consensus estimate of HK$0.222 by -HK$0.127.
Is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pay dividends?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pays a Annually dividend of HK$0.166 which represents an annual dividend yield of 4.16%. See more information on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H dividends here
What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s EPS estimate?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s EPS estimate is 0.12.
How many shares outstanding does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H have?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has 220,094,500 shares outstanding.
What happened to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price movement after its last earnings report?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H reported an EPS of HK$0.095 in its last earnings report, missing expectations of HK$0.222. Following the earnings report the stock price went down -1.648%.
Which hedge fund is a major shareholder of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9989
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology